Home›US Markets›Sectors›Dr Lal PathLabs to buy 70% of SN Genelab for up to Rs…

Dr Lal PathLabs to buy 70% of SN Genelab for up to Rs 168 crore

The deal also includes an additional earn-out of Rs 31.5 crore, according to LiveMint Markets.

Reported · Written up by our desk · Sectors

Investors in India are set to track several stocks on September 24, after a series of corporate developments, including acquisitions and fundraising plans, according to LiveMint Markets.

LiveMint Markets said the Indian market closed lower on Thursday, with the Nifty 50 down 1.6% to 25,169.5 and the Sensex finishing down 1.7% at 73,580.

Among the companies in focus, Dr Lal PathLabs plans to acquire a 70% stake in SN Genelab Private Limited from its existing shareholders for up to Rs 168 crore.

LiveMint Markets added that the purchase price includes an additional earn-out of Rs 31.5 crore, and that SN Gene would become a subsidiary of Dr Lal PathLabs after the acquisition.

Latest closeSensex 73,580.54 ▼1.7%

More like this

Sources